Pure Global AI
NCT05982873Available

Expanded Access to ABBV-400

AbbVieClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Non-Small Cell Lung Cancer
Drug/Device/Intervention
ABBV-400
Intervention type
drug
Sponsor & location
Primary sponsor
AbbVie
Timeline & enrollment
Phase
N/A
Start date
N/A
End date
N/A
Summary

This is an expanded access program (EAP) for eligible participants. This program is designed
 to provide access to ABBV-400 prior to approval by the local regulatory agency. Availability
 will depend on territory eligibility. A medical doctor must decide whether the potential
 benefit outweighs the risk of receiving an investigational therapy based on the individual
 patient's medical history and program eligibility criteria.

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05982873
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05982873 through Pure Global AI's free database. This phase not specified trial is sponsored by AbbVie and is currently Available. The study focuses on Non-Small Cell Lung Cancer.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.